NP
BMY icon

NorthRock Partners’s Bristol-Myers Squibb BMY Stock Holding History

NorthRock Partners’s Portfolio BMY Stock Details BMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$441K Buy
7,276
+968
+15% +$56.4K 0.01% 432
2025
Q4 		$340K Sell
6,308
-26,594
-81% -$1.28M 0.01% 448
2025
Q3 		$1.48M Buy
32,902
+5,226
+19% +$244K 0.03% 259
2025
Q2 		$1.28M Sell
27,676
-1,059
-4% -$52K 0.03% 199
2025
Q1 		$1.75M Buy
28,735
+1,976
+7% +$115K 0.06% 132
2024
Q4 		$1.51M Buy
26,759
+594
+2% +$33.2K 0.05% 146
2024
Q3 		$1.35M Buy
26,165
+9,142
+54% +$429K 0.04% 175
2024
Q2 		$707K Buy
17,023
+1,486
+10% +$66.5K 0.03% 257
2024
Q1 		$843K Buy
15,537
+1,250
+9% +$63.7K 0.03% 230
2023
Q4 		$733K Buy
14,287
+3,781
+36% +$198K 0.03% 234
2023
Q3 		$610K Buy
10,506
+624
+6% +$38.2K 0.06% 129
2023
Q2 		$632K Buy
9,882
+664
+7% +$44.5K 0.07% 112
2023
Q1 		$639K Sell
9,218
-2,360
-20% -$166K 0.07% 125
2022
Q4 		$833K Buy
11,578
+3,459
+43% +$261K 0.09% 110
2022
Q3 		$577K Sell
8,119
-1,045
-11% -$75.8K 0.07% 131
2022
Q2 		$706K Sell
9,164
-223
-2% -$17K 0.07% 120
2022
Q1 		$686K Buy
9,387
+2,379
+34% +$160K 0.06% 141
2021
Q4 		$437K Buy
7,008
+1,460
+26% +$85.6K 0.03% 192
2021
Q3 		$328K Buy
5,548
+571
+11% +$37.6K 0.03% 200
2021
Q2 		$333K Buy
4,977
+251
+5% +$16.4K 0.03% 184
2021
Q1 		$298K Sell
4,726
-1,604
-25% -$99.8K 0.03% 176
2020
Q4 		$393K Sell
6,330
-981
-13% -$60.3K 0.04% 147
2020
Q3 		$441K Sell
7,311
-1,056
-13% -$63.6K 0.05% 131
2020
Q2 		$492K Buy
8,367
+414
+5% +$24.8K 0.06% 118
2020
Q1 		$443K Sell
7,953
-6,052
-43% -$370K 0.06% 118
2019
Q4 		$899K Buy
14,005
+8,750
+167% +$501K 0.1% 107
2019
Q3 		$266K Buy
+5,255
New +$247K 0.04% 181
2019
Q1 		– Sell
-4,480
Closed -$232K – 96
2018
Q4 		$232K Buy
+4,480
New +$241K 0.07% 82

Other funds holding BMY

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

NorthRock Partners's BMY Position: Q1 2026 in Review

NorthRock Partners increased its Bristol-Myers Squibb (BMY) stake by 15% in Q1 2026, buying an estimated $56.4K and bringing the position to 7,276 shares worth $441K. The position accounts for 0.01% of the portfolio, ranked #432.

NorthRock Partners first reported a position in BMY in Q4 2018 and has held it in 28 quarters since. The position peaked at $1.75M in Q1 2025. 2,520 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • NorthRock Partners held 7,276 shares of Bristol-Myers Squibb worth $441K as of Q1 2026.
  • NorthRock Partners bought 968 Bristol-Myers Squibb shares in Q1 2026, an estimated $56.4K.
  • Bristol-Myers Squibb made up 0.01% of NorthRock Partners's portfolio in Q1 2026, its #432 holding.
  • NorthRock Partners first reported a position in Bristol-Myers Squibb in Q4 2018 and has held it in 28 quarters since.
  • NorthRock Partners's Bristol-Myers Squibb position peaked at $1.75M in Q1 2025.
  • 2,520 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on NorthRock Partners's 13F filing for Q1 2026, filed 15 May 2026.